SGLT2 inhibitor use has fewer adverse events compared to GLP-1 receptor agonists in heart failure patients with mildly reduced or preserved ejection fraction
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.